Recollections of the 60th Annual ASH Meeting and Expo

Jim Omel |

ASH is over but its memories are fresh. My strongest impression of the meeting is that multiple myeloma treatment advances continue to be significant at this huge yearly event. Dr. Durie explained there were an amazing 939 abstracts relating to myeloma at ASH this year. At the IMWG (International Myeloma Working Group) meeting, he said […]

Day 3 – Saving the Best for Last

Jack Aiello |

December 3, 2018 Yes, today was the last full day of ASH, but that’s not to say it wasn’t full of information with oral presentations packing the day from 7:00 a.m.–7:45 p.m. Highlights included (# abstract number): Isatuximab-Vel-Rev-dex (Isa-VRd) for Newly Diagnosed Non-stem-cell-transplant-eligible myeloma patients (#595): This four-drug phase I study for 27 patients reported […]

With Myeloma, Even a 20-year Survivor Always Has More to Learn

Yelak Biru |

Anytime you can reduce dexamethasone (dex), do it  There was one specific trial that was presented at this year’s ASH that studied the benefit of dex. The study was conducted with 199 intermediate fit patients with Revlimid and dexamethasone (Rd) induction (9 cycles) and Revlimid (R) maintenance until progression compared to Rd induction and Rd […]

Snoopy Philosophy

John DeFlice |

CHARLIE BROWN:  Someday we will die, Snoopy. SNOOPY:  True, but all the other days, we will not. Snoopy’s philosophy resonates at ASH 2018 because of all the exciting information on immunotherapy.  There are new approaches to the use of daratumumab with other agents in quadruple combinations that result in high rate of response in newly […]

Day 2: A Busy Day at ASH

Jack Aiello |

Day 2: A busy day at ASH December 2, 2018 Today I attended oral presentations from 8 a.m. to 6 p.m. with a few short breaks to check out posters and exhibits as well as meet with Pharma companies. Let me discuss several findings from several oral presentations (#abstract). Maintenance Therapy with Ninlaro (Ixazomib)….Tourmaline 3 […]